A New Venture for Health Systems — Biotech Investing

Watch expert panel discussion to learn why health systems are playing a larger role in the commercialization of biotech and therapeutic startups

Health systems are increasingly the source of scientific innovation that not only leads to new treatments for diseases but also the commercialization activity and funding for biotech startups.

This panel of health system investment leaders from Johns Hopkins, Mass General Brigham, and UPMC discusses how and why their organizations are taking an active role in funding innovation and commercialization in life sciences. The experts also discuss how their strategies differ from traditional venture investors.

Moderated by an experienced venture capitalist from Lightstone Ventures, the panel addresses:

How proximity to clinicians and researchers can catalyze the identification and acceleration of the most impactful ideas.
Which intangible assets and value health system investors can bring to bear.
How they can bridge early-stage funding.
Partnerships that can accelerate discoveries from bench to bedside.

Based on the latest research report from the Center for Connected Medicine, “A New Player in Biotech Investing,” which identifies 15 health systems leading in company formation and venture investing, the panel delivers insights on a vital new player in the creation of therapies.

WATCH ON-DEMAND

Expert panelists

The CCM is pleased to host the discussion and feature the following experts:

Christina Isacson, PhD, Partner, Lightstone Ventures (Moderator)
Roger Kitterman, MBA, Managing Partner, Mass General Brigham Ventures, and Vice President, Mass General Brigham Innovation
Matthias Kleinz, DVM, PhD, Senior Vice President, Translational Sciences, UPMC Enterprises
Sashank Reddy, MD, Senior Medical Director, Johns Hopkins Technology Ventures and Assistant Professor of Plastic and Reconstructive Surgery, Johns Hopkins University School of Medicine